Reven Stock

reven.comHealthcareFounded: 1999Funding to Date: $106.23MM

Reven Pharmaceuticals is a biopharmaceutical company developing solutions for those suffering the effects of vascular and metabolic related diseases.

Register for Details

For more details on financing and valuation for Reven, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Reven.

Register Today

Team

Management Team

Brian Denomme
Chief Operating Officer & Board Member
Michael Volk
Chief Financial Officer & Board Member
James Ervin
Chief Technology Officer
Peter Lange
Founder, Board Member & Chief Executive Officer
Henk Van Wyk
Chief Scientist

Board Members

Brian Denomme
Chief Operating Officer & Board Member
Michael Volk
Chief Financial Officer & Board Member
Peter Lange
Founder, Board Member & Chief Executive Officer

Other companies like Reven in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
 
 
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$1.59B
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 

News

New Delhi, India -- (SBWIRE) -- 04/09/2018 -- Critical Limb Ischemia (CLI) is a severe form of peripheral artery disease (PAD). It occurs with severe obstructions in the arteries which leads to reduced blood flow to the extremities.
There has been $13.1 billion invested across 1,287 deals so far this year